Buoyed by 6-week hep C data, Achillion sets out to test even faster cure
February 9, 2015 | By John Carroll
Now researchers are using the data to set the stage to see if the results can be replicated even faster in a 4-week trial. Competing drugs from Gilead and AbbVie have forced out earlier standard remedies with oral combos that are much easier to tolerate and much more likely to provide a lasting cure. The goal now is to find ways to do it quicker and with less expense, providing an opening for some of the companies still in the hunt.
"The ability to further shorten treatment duration to only six weeks and maintain excellent SVR12 rates remains the goal for clinicians and patients, and I am pleased that these Phase 2 results support that goal.The profile of ACH-3102, represents an important and exciting treatment option to shorten treatment durtion for patients infected with HCV," commented Professor Edward Gane, the lead investigator in the study
@adamfeuerstein $ADXS $INCY collaborating on combo I-O study in cervical cancer is huge for I-O combo data.
just look at the charts !!
common sense peeps.
2/19 Security high on agenda as CyberArk blows analysts out of the water
Security high on agenda as CyberArk blows analysts out of the water “It has become increasingly clear that privileged account security is the critical new layer of protection for organizations."James Henderson (New Zealand Reseller News) on 19 February, 2015
im in peeps